Despite New Approvals, Covid-19 Treatments Lag Behind Vaccines
The EU recently added two drugs to its list of approved Covid-19 treatments. Yet with…
25/11/2021 - 6 minutes
News and Trends
Investors Flock to Startups Reprogramming Cell Therapies
Painstaking and expensive procedures are required to produce human cells for use in research and…
22/11/2021 - 7 minutes
Sustainability in Focus as Two VCs Build Industrial Biotech Funds
As this month’s COP26 United Nations climate summit highlighted the climate change emergency, venture capital…
18/11/2021 - 4 minutes
Vaccine Biotechs Gear Up to Take On Covid-19 Variants
Vaccines for Covid-19 are rolling out all over the world, but their protection is threatened…
15/11/2021 - 7 minutes
Big Pharma Strikes Megadeals In Targeted Protein Degradation
With many targeted protein degraders hitting the clinic, lucrative collaborations and acquisitions are being signed…
12/11/2021 - 5 minutes
Evotec IPO Hints At Stabilizing Investor Interest In Biotech Stocks
German life sciences heavyweight Evotec raised around €376M ($435M) in its US debut on the…
10/11/2021 - 4 minutes
Skilled Labor Shortages Impact Cell And Gene Therapy Manufacturing
Despite vast amounts of funding entering the cell and gene therapy field, the manufacture of…
04/11/2021 - 5 minutes
The Top European Biotech Investment Rounds in October
DNA manufacturing was a hot topic in biotech investments in October, with immuno-oncology and insect…
02/11/2021 - 5 minutes
DNA Manufacturing Startups Net Venture Capital Windfalls
Touchlight Genetics and DNA Script have closed major venture financing rounds in the last month…
28/10/2021 - 6 minutes
Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial
Last week, the French vaccine maker Valneva announced promising phase III trial results of its…
26/10/2021 - 5 minutes
Gene-Edited T Cell Therapy Players Battle Safety Doubts
Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused…
22/10/2021 - 5 minutes
Biotech VCs Face Funding Bulge Amid Struggling Stock Markets
Despite volatile biotech stocks limiting options for exit, Sofinnova Partners’ latest €472M fund highlights ballooning…
19/10/2021 - 5 minutes
